<DOC>
	<DOCNO>NCT00460083</DOCNO>
	<brief_summary>Atopic dermatitis ( AD ) common skin disease increase prevalence worldwide two- threefold last 50 year . Epiceram , newly FDA-approved medical device topical barrier repair cream design deliver special epidermal lipid top layer skin order correct skin barrier abnormality find atopic dermatitis . Epiceram contain corticosteroid conventional anti-inflammatory component represent novel class skin barrier repair therapy inflammatory skin disease . The objective study determine whether Epiceram safe effective therapy mild moderate atopic dermatitis whether may serve alternative Elidel therapy .</brief_summary>
	<brief_title>Epiceram Versus Elidel Treatment Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description>Atopic dermatitis ( AD ) common skin disease increase prevalence worldwide two- threefold last 50 year . Current standard care atopic dermatitis include topical corticosteroid calcineurin inhibitor , Elidel Protopic . The chronic use topical corticosteroid limit side effect include skin atrophy , stria , even HPA axis suppression . The long-term effect skin immunosuppression calcineurin inhibitor unknown although proven , theoretical risk skin cancer exist . Novel therapy atopic dermatitis avoid immunosupression greatly need . Epiceram , newly FDA-approved medical device topical barrier repair cream design deliver special epidermal lipid top layer skin order correct skin barrier abnormality find atopic dermatitis . Epiceram contain corticosteroid conventional anti-inflammatory component represent novel class skin barrier repair therapy inflammatory skin disease . The objective study determine whether Epiceram safe effective therapy mild moderate atopic dermatitis whether may serve alternative Elidel therapy .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Decanoic acid</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<criteria>1 . Males females race 2 12 year age . 2 . Diagnosis atopic dermatitis basis criterion define Hanifin Rajka ( Hanifin , 1980 ) . 3 . RajkaLangeland Severity Index score mild moderate ( Rajka , 1989 ) . 4 . At least one antecubital popliteal fossa must affect time enrollment serve target site . 1 . Subjects severe AD determine RajkaLangeland Severity Index ( Rajka 1989 ) . 2 . Disease severity require mediumpotency topical steroid medication treat atopic dermatitis 1 week per month . 3 . Subjects unstable uncontrolled medical condition could require intensive treatment course study . 4 . Subjects require great 2.0 mg/day inhale intranasal corticosteroid . 5 . Subjects currently participate , within past 28 day , participate another study use investigational drug . 6 . Subjects history allergy hypersensitivity Epiceram , Elidel , ingredient therein , include fragrance . 7 . Active infection type start study . 8 . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . 9 . Subjects must use topical systemic therapy washout period .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>eczema</keyword>
	<keyword>dermatitis</keyword>
	<keyword>skin barrier</keyword>
	<keyword>barrier repair</keyword>
	<keyword>ceramide</keyword>
	<keyword>physiologic lipid</keyword>
	<keyword>pruritus</keyword>
	<keyword>Elidel</keyword>
	<keyword>Epiceram</keyword>
	<keyword>topical steroid</keyword>
</DOC>